- Covovax is 9th vaccine approved in Philippines
- Novavax requests emergency use in Europe, Canada
MANILA, Nov. 17 (Reuters) – The Philippines has approved the emergency use of a COVID-19 vaccine by Novavax Inc (NVAX.O), the head of the food and drug agency said Wednesday, the ninth vaccine approved in the Southeast. -Asian country.
The nanoparticle vaccine, under the brand name Covovax, will be manufactured by the Serum Institute of India and approved for use in adults ages 18 and older, Rolando Enrique Domingo, the agency’s chief, told a public briefing.
Covovax, which had an efficacy of 89.7% in clinical trials, will be given in two doses no less than 21 days apart, Domingo added.
The Philippines has vaccinated more than a quarter of its 110 million population.
Early this month, Novavax received its first emergency use authorization from Indonesia. Novavax has also applied for approval of the vaccine in Canada and with the European Medicines Agency.
Reporting by Neil Jerome Morales; Editing by Martin Petty
Our Standards: The Thomson Reuters Trust Principles.